• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Trump Says White House Could Reject Stricter COVID-19 Vaccine Requirements

Trump Says White House Could Reject Stricter COVID-19 Vaccine Requirements

September 28, 2020

In a stunning departure from how FDA guidances are issued by the agency, President Donald Trump said Wednesday evening that he might move to reject a guidance that is expected to impose stricter thresholds for any COVID-19 vaccine Emergency Use Authorizations (EUAs).

“We’re looking at [the guidance], and that has to be approved by the White House,” the president said during a press briefing. “We may or may not approve it. I think [it] was a political move more than anything else.”

It would likely be the first time that the White House has gotten so directly involved with the issuance of an agency guidance. The guidance is expected to require vaccine manufacturers pursuing an EUA to track phase 3 trial participants for at least two months after vaccination and to include at least five severe COVID-19 cases and some cases in older patients in a trial’s placebo group.

The guidance would make it near impossible for an EUA to be approved before the Nov. 3 presidential election. The president has repeatedly expressed optimism that a vaccine will be delivered before the election, perhaps as soon as October, he has said, leading to accusations from more than a few former FDA officials and other leading public health officials that he is politically strong-arming the agency to rush an authorization or approval to help his reelection prospects.

The president has previously accused the FDA of political bias, while the agency has been equally adamant in its denials of alleged bias. FDA Commissioner Stephen Hahn has publicly offered reassurance that the agency would be led only by science in its decisions on COVID-19 vaccines and treatments and has vowed that he would resign rather than be forced to rush through a vaccine approval.

COVID-19
  • Related Directories

    Olumiant (baricitinib)

    Veklury (remdesivir)

    Comirnaty (COVID-19 Vaccine, mRNA)

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing